Aspirin Mouthwash in Treating Patients With Oral Leukoplakia

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Aspirin mouthwash may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of aspirin mouthwash in treating patients with oral leukoplakia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Head and Neck Studies and Education, United Kingdom
• Treatments: Aspirin; Cyclooxygenase Inhibitors

Criteria

DISEASE CHARACTERISTICS:

• Clinically diagnosed oral leukoplakia requiring a tissue biopsy for histological diagnosis

• Attending the outpatient clinic

PATIENT CHARACTERISTICS:

• Not nursing

• No known or suspected sensitivity to aspirin or other nonsteroidal anti-inflammatory drugs

• No diagnosis of asthma or angioedema

• No contraindications, including any of the following:

• Active peptic ulceration or a history of peptic ulceration

• Hemophilia or a history of bleeding disorders

• Gout or a history of gout

PRIOR CONCURRENT THERAPY:

• No concurrent regular use of aspirin for heart disease or other reasons

• No other concurrent nonsteroidal anti-inflammatory drugs